Myriad Genetics, a leader in molecular diagnostics and precision medicine, announced that Medicare has expanded coverage for BRACAnalysis CDx^® for men with prostate cancer who are eligible or could become eligible for treatment with Lynparza^® (olaparib). BRACAnalysis CDx is the only germline test covered for this indication.

To view full press release click here: PRESS RELEASE

If you would like to learn more about BRACAnalysis CDx^® or MyRisk^®, click here.